ESR1 and cancer: Lastly, resistance to aromatase inhibitor therapy is mediated via epigenetic reprogramming to upregulate cholesterol biosynthesis pathway and 27-hydroxy cholesterol that eventually promote cellular invasion and in turn cause the constitutive activation of ER alpha leading to cancer cells that are refractory to therapies [23].